


Ask a doctor about a prescription for OLANZAPINE AUROVITAS 2.5 mg TABLETS
Package Leaflet: Information for the User
Olanzapina Aurovitas 2.5 mg Tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Olanzapina Aurovitas belongs to a group of medications called antipsychotics and is indicated for the treatment of the following diseases:
? Schizophrenia, a disease whose symptoms are hearing, seeing, or feeling unreal things, mistaken beliefs, unusual suspicion, and becoming withdrawn. People suffering from these diseases may also be depressed, anxious, or tense.
? Moderate to severe manic disorder, characterized by symptoms such as excitement or euphoria.
Olanzapine has been shown to prevent the recurrence of these symptoms in patients with bipolar disorder whose manic episodes have responded to treatment with olanzapine.
Do not take Olanzapina Aurovitas
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Olanzapina Aurovitas.
If you suffer from any of the following diseases, tell your doctor as soon as possible:
If you suffer from dementia, you or your caregiver or family member should inform your doctor if you have ever had a stroke or cerebral ischemia.
As a routine precaution, if you are over 65 years old, it would be advisable for your doctor to check your blood pressure.
Children and Adolescents
Patients under 18 years old should not take olanzapine.
Taking Olanzapina Aurovitas with Other Medications
Only use other medications at the same time as olanzapine if your doctor authorizes it. You may feel drowsy if you combine olanzapine with antidepressants or medications for anxiety or sleep aids (tranquilizers).
Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
In particular, tell your doctor if you are taking:
Taking Olanzapina Aurovitas with Alcohol
You should not drink alcohol if you have been administered Olanzapina Aurovitas, as it may cause drowsiness.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication. You should not take this medication while breastfeeding, as small amounts of olanzapine may pass into breast milk.
Newborns of mothers who have used Olanzapina Aurovitas in the last trimester of pregnancy may experience the following symptoms: tremors, muscle stiffness and/or weakness, drowsiness, agitation, breathing problems, and feeding difficulties. If your newborn experiences any of these symptoms, contact your doctor.
Driving and Using Machines
There is a risk of drowsiness when taking olanzapine. If this happens to you, do not drive vehicles or use machinery. Consult your doctor.
Olanzapina Aurovitas Contains Lactose
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow your doctor's instructions for taking this medication exactly. If you are unsure, consult your doctor or pharmacist again.
Your doctor will tell you how many olanzapine tablets to take and for how long. The daily dose of olanzapine ranges from 5 mg to 20 mg. Consult your doctor if you experience symptoms again, but do not stop taking olanzapine unless your doctor tells you to.
You should take your olanzapine tablets once a day, following your doctor's instructions. Try to take the tablets at the same time every day. You can take them with or without food. Olanzapina Aurovitas tablets are for oral administration. You should swallow the tablets whole with water.
If You Take More Olanzapina Aurovitas Than You Should
Patients who have taken more olanzapine than they should have experienced the following symptoms: rapid heartbeat, agitation/aggression, speech problems, unusual movements (especially of the face and tongue), and a reduced level of consciousness. Other symptoms may include: acute confusion, seizures (epilepsy), coma, a combination of fever, rapid breathing, sweating, muscle stiffness, and a state of confusion or drowsiness, slowed breathing rate, aspiration, increased or decreased blood pressure, and abnormal heart rhythms. Contact your doctor or go to the hospital immediately. Show the doctor the package with the tablets.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If You Forget to Take Olanzapina Aurovitas
Take your tablets as soon as you remember. Do not take a double dose to make up for forgotten doses.
If You Stop Taking Olanzapina Aurovitas
Do not stop treatment just because you feel better. It is very important that you continue taking olanzapine while your doctor tells you to.
If you stop taking olanzapine suddenly, you may experience symptoms such as sweating, insomnia, tremors, anxiety, or nausea and vomiting. Your doctor may suggest that you gradually reduce the dose before stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone experiences them.
Contact your doctor immediately if you experience:
Severe allergic reactions, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported. DRESS initially manifests with symptoms similar to those of the flu, with a skin rash on the face that then spreads to other areas, fever, swelling of lymph nodes, elevated liver enzymes in blood tests, and an increase in a type of white blood cell (eosinophilia).
Very Common(may affect more than 1 in 10 people) include: weight gain, drowsiness, and increased prolactin levels in the blood.
In the early stages of treatment, some people may feel dizzy or faint (with slower heartbeats), especially when getting up from a lying or sitting position. This sensation usually disappears on its own, but if it does not, inform your doctor.
Common(may affect up to 1 in 10 people) include:
Uncommon(may affect up to 1 in 100 people) include:
Rare(may affect up to 1 in 1,000 people) include:
During treatment with olanzapine, elderly patients with dementia may experience stroke, pneumonia, urinary incontinence, falls, extreme fatigue, visual hallucinations, increased body temperature, skin redness, and walking problems. Some deaths have been reported in this particular group of patients.
Olanzapine may worsen symptoms in patients with Parkinson's disease.
Reporting Side Effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date shown on the box and blister pack after EXP. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in the pharmacy. Ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Olanzapina Aurovitas
Appearance of the Product and Contents of the Pack
Uncoated yellow tablets (5.2 mm in diameter), round, biconvex, with the mark "OA" on one side and "2.5" on the other.
Olanzapina Aurovitas tablets are available in PVC/Poliamide/Al/PVC/Al blister packs of 7, 14, 28, 30, 35, 50, 56, 70, 96, 98, and 100 tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
Manufacturer:
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
This medication is authorized in the Member States of the European Economic Area under the following names:
Spain: | Olanzapina Aurovitas 2.5 mg tablets EFG |
Portugal: | Olanzapina Aurovitas |
Date of the Last Revision of this Package Leaflet: June 2020
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
The average price of OLANZAPINE AUROVITAS 2.5 mg TABLETS in October, 2025 is around 13.22 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for OLANZAPINE AUROVITAS 2.5 mg TABLETS – subject to medical assessment and local rules.